Silence Therapeutics (SLN) Other Operating Expenses (2024 - 2025)
Silence Therapeutics (SLN) posted Other Operating Expenses of -$4.0 million for Q2 2025, up 85.95% sequentially from -$28.4 million in Q1 2025, and up 78.62% YoY from -$2.2 million in Q2 2024.
Silence Therapeutics (SLN) Other Operating Expenses (2024 - 2025) Analysis & Trends
Silence Therapeutics has reported Other Operating Expenses for 2 years, with the latest figure at -$4.0 million in Q2 2025.
- Quarterly Other Operating Expenses rose 78.62% year-over-year to -$4.0 million in Q2 2025, while the trailing twelve-month figure through Mar 2026 was -$4.0 million (up 91.52% YoY) and the FY2024 annual result came in at -$113.6 million, changed N/A from the prior year.
- Other Operating Expenses grew to -$4.0 million in Q2 2025 per SLN's latest filing, from -$28.4 million in the prior quarter.
- Over five years, Other Operating Expenses peaked at -$4.0 million in Q2 2025 and troughed at -$28.4 million in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Silence Therapeutics | 648.22 Mn | 576.12 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | -3.99 Mn |
| Mar 31, 2025 | -28.38 Mn |
| Jun 30, 2024 | -18.64 Mn |
| Mar 31, 2024 | -10.77 Mn |